Anavex Life Sciences

AVXLNASDAQUSD
3.03 USD
0.04 (1.17%)🟢LIVE (AS OF 12:56 PM EDT)
🟢Market: OPEN
Open?$3.02
High?$3.09
Low?$2.98
Prev. Close?$2.99
Volume?332.5K
Avg. Volume?1.8M
VWAP?$3.05
Rel. Volume?0.19x
Bid / Ask
Bid?$3.03 × 400
Ask?$3.04 × 400
Spread?$0.01
Midpoint?$3.04
Valuation & Ratios
Market Cap?277.1M
Shares Out?92.7M
Float?84.7M
Float %?94.8%
P/E Ratio?N/A
P/B Ratio?2.19
EPS?-$0.43
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?23.89Strong
Quick Ratio?23.89Strong
Cash Ratio?23.67Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A
P/B?
2.19CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
-3.3CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
-31.6%WEAK
ROA?
-30.0%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$145.3M
Related Companies
Loading...
News
Profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Employees
34
Market Cap
277.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2006-08-02
Address
630 5TH AVENUE
NEW YORK, NY 10111
Phone: 844-689-3939